Wellington Management Group LLP lowered its position in Inhibrx, Inc. (NASDAQ:INBX – Free Report) by 16.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 145,398 shares of the company’s stock after selling 29,501 shares during the period. Wellington Management Group LLP owned 0.31% of Inhibrx worth $5,525,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Vestal Point Capital LP acquired a new stake in Inhibrx during the 4th quarter valued at $58,140,000. RA Capital Management L.P. increased its stake in shares of Inhibrx by 22.6% in the third quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock valued at $86,689,000 after buying an additional 870,340 shares in the last quarter. PFM Health Sciences LP raised its holdings in shares of Inhibrx by 86.4% in the fourth quarter. PFM Health Sciences LP now owns 537,964 shares of the company’s stock valued at $20,443,000 after buying an additional 249,347 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Inhibrx during the 4th quarter worth about $894,000. Finally, Vanguard Group Inc. grew its holdings in Inhibrx by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,789,811 shares of the company’s stock worth $32,843,000 after acquiring an additional 18,271 shares during the last quarter. 82.46% of the stock is owned by institutional investors and hedge funds.
Inhibrx Stock Up 0.8 %
Shares of NASDAQ INBX opened at $14.17 on Friday. Inhibrx, Inc. has a 1-year low of $13.67 and a 1-year high of $18.95. The company has a 50-day moving average of $26.47 and a two-hundred day moving average of $32.29.
Insider Activity at Inhibrx
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- Health Care Stocks Explained: Why You Might Want to Invest
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 6/24 – 6/28
- Options Trading – Understanding Strike Price
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.